Neumora Therapeutics, a Phase III US biotech developing therapies for brain diseases, announced terms for its initial public offering (IPO) on Monday. 12 September 2023
US clinical-stage liver disease drug developer Madrigal Pharmaceuticals today announced that Bill Sibold has succeeded Dr Paul Friedman as the firm’s chief executive and joined Madrigal’s board of directors. 11 September 2023
Florida, USA-based biotech Veru has expressed its confidence in breast cancer candidate enobosarm, citing data from a discontinued Phase III trial. 11 September 2023
German drug developer Immatics saw its shares rise as much as 6.6% to $12.98 pre-market, after its announced a strategic research and development collaboration with US biotech Moderna. 11 September 2023
Shares of US drug developer Crinetics Pharmaceuticals shot up more than 66%% to $26.60 pre-market, after its experimental treatment for a rare hormonal disorder not only succeeded, but performed better than Wall Street expectations. 11 September 2023
Boston, USA-based Glyscend Therapeutics, which is developing a revolutionary approach to treating type 2 diabetes, has appointment of Sapan Shah as chief executive (CEO). 8 September 2023
US biopharma CymaBay Therapeutics traded up as much as 21% to $16.73 yesterday, as the company released encouraging trial results for its primary biliary cholangitis (PBC) candidate after earlier disappointments. 8 September 2023
US clinical-stage biopharma Nurix Therapeutics saw its shares rise almost 11% to $9.19 yesterday morning, after it announced a multi-year, multi-target strategic collaboration agreement with Seagen. 8 September 2023
UK cancer and infectious disease drug developer Scancell Holdings has appointed Dr Mandeep Sehmi as head of business development, effective immediately. 8 September 2023
Acquisitive US biotech Kriya Therapeutics yesterday revealed that it has acquired Tramontane Therapeutics, a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases. 7 September 2023
US biotech Star Therapeutics has announced the closing of an oversubscribed $90 million Series C financing to continue growing its antibody therapies and portfolio companies. 5 September 2023
Italy’s privately-held drug developer Italfarmaco Group today revealed that its Marketing Authorization Application (MAA) for Givinostat as a potential treatment for Duchenne muscular dystrophy (DMD) has been submitted to the European Medicine Agency. 5 September 2023
Dutch specialty pharma firm Pleco Therapeutics has appointed Dr Henno Welgemoed in the newly created role of chief medical officer (CMO). 5 September 2023
Shares of Swedish enzyme technology firm Hansa Biopharma were up 3% at 43.82 kronor, after it announced the appointment of Dr Hitto Kaufmann as its chief scientific officer (CSO) effective December 1, 2023. 1 September 2023
Reeling from a regulatory setback last month, Sage Therapeutics is to undergo a major restructuring in the run-up to its launch of postpartum depression drug Zurzuvae (zuranolone). 1 September 2023
Ireland-headquartered Ovoca Bio saw its shares plunge 82% to 2.50 pence yesterday, after it revealed disappointing results from a Phase II dose ranging study assessing orenetide conducted in Australia and New Zealand. 1 September 2023
US synthetic DNA producer Twist Bioscience today announced a drug discovery agreement with Japan’s Ono Pharmaceutical to discover and develop novel antibodies for the treatment of autoimmune diseases. 31 August 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024